Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2026 Earnings Presentation
15 slides from Vita Life Sciences's earnings presentation, Aug 18, 2026
Slide 1: Half Year Presentation
Half Year Presentation Jun 2026
Slide 2: About Vita Life Sciences
About Vita Life Sciences is an Australian owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our core business is the Vita Life development and distribution of over the counter (OTC) medicines, as well as complementary and alternative medicines, dietary suppleme
Slide 3: Operational highlights
Operational highlights Broad based growth across core markets, supported by strong performances across all major channels and positive consumer sentiment. • Australia up 14% • Malaysia & Singapore up 7% • Vietnam up 59% Market initiatives • Continued distribution expansion in Australia, Malaysia and
Slide 4: Financial Highlights
REVENUE Financial PBT $48.3M Highlights $8.1M UP 6% VS PCP Half year UP 19% VS PCP • Record full year performance dividend • Gross profit margin ↑ 3% to 64% 5.0CPS EQUITY $55.7M CASH • Cash conversion: strong 91% RESERVES • Strong balance sheet with no borrowings $33.7M (no borrowing) • Share buybac
Slide 5: Half Year Results
Half Year Results REVENUE 2026 2025 $48.3M Half year ended June $’m $’m Revenue 48.3 45.5 EBITDA 8.2 7.0 PBT EBIT Profit before tax 7.7 8.1 6.4 6.8 $8.1M Profit after tax 5.5 4.8 EPS (Basic – cents/ share) 10.22 8.61 Dividend (cents / share) 5.0 4. 5
Slide 6: Balance Sheet
Balance Sheet Jun 2026 Dec 2025 Balance Sheet as at $’m $’m Current assets 64.7 65.8 Non-current assets 15.7 16.6 Total assets 80.4 82.4 Current liabilities 22.9 24.2 Non-current liabilities 1.8 2.0 Total Liabilities 24.7 26.2 Net Assets 55.7 56.2
Slide 7: Cash Flow
Cash Flow 2026 2025 Cash Flow for the half year ended June $’m $’m Receipts from customers 49.6 47.0 GROSS Payments to suppliers and employees (42.1) (39.5) OPERATING CASH FLOW 91% Gross operating cash flow 7.5 7.5 EBITDA 8.2 6.9 Gross operating cash flow / EBITDA 91% 109% Net interest 0.4 0.2 Incom
Slide 8: Delivering disciplined growth and margin resilience
Profitable, cash-generative healthcare business Delivering disciplined Strong channel growth and performance Margin resilience margin despite competitive resilience pressures Clear focus on profitable growth and execution Disciplined capital management and balance sheet strength
Slide 9: Marketing Initiatives
Marketing Initiatives Building stronger brands. Creating demand. Driving sustainable growth. Our marketing efforts are focused on building strong, trusted and premium brands across the VLS Group. Through clear positioning, targeted investment and impactful execution, we drive consumer demand, brand
Slide 10: NPD HY 2026
NPD HY 2026 350 products There are currently over 7 new products registered across the business. launched across Australia, Malaysia and Singapore.
Slide 11: Our Brands
Our Brands Herbs of Gold is an Australian brand that was VitaHealth first started in 1947 as a retail VitaScience was launched in 2002 as a vivacious founded in 1989. By utilising traditional evidence pharmacy. It offers a comprehensive range of nutritional supplement brand. It is committed to combi
Slide 12: Our People Our Markets Our Partners
Our People Our Markets Our Partners AUSTRALIA MALAYSIA SINGAPORE OVER 250 VIETNAM CHINA OVER 3000 EMPLOYEES RETAILERS We have over 250 employees in the Vita Life Sciences We continue to evolve and expand our Our products are available across some of the Group across Australia, Malaysia, Singapore, C
Slide 13: Social impact & corporate responsibility
Social impact & corporate responsibility At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We have developed partnershi
Slide 14: Slide 14
Slide 15: Thank you
Thank you slide Thank you